Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other or... ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting today, Monday, November 3rd, at 09:45am ET at the Spartan Capital Investor Conference 2025 in New York City. Event Information: Event NanoViricides Presentation at the Spartan Capital Investor Conference - 2025, New York, NY Track 2 Date Monday, N ...

ORLADEYO Performance and Outlook - ORLADEYO revenue continues strong growth, with a 37% year-over-year increase in Q3 2025[15] - The FY25 guidance range for ORLADEYO revenue has been raised to $590-600 million[17] - Market research reaffirms a strong outlook for ORLADEYO, with an estimated patient LTP share of 24% in 2034[19] - BioCryst anticipates a sustainable $1 billion peak revenue opportunity for ORLADEYO, with a contribution margin exceeding 80%[14] Astria Acquisition and HAE Portfolio Expansion - BioCryst is set to acquire Astria for approximately $700 million TEV, aiming to strengthen its presence in the HAE market[30] - The acquisition is expected to transform BioCryst's revenue profile, projecting a 10+ year double-digit portfolio CAGR[30] - Post-transaction, BioCryst anticipates maintaining profitability (non-GAAP) and positive cash flow[31] - By 2029, the company expects a cash balance of over $1 billion, providing flexibility for future growth opportunities[32] Pipeline Development - Navenibart presents an opportunity to target 5,000+ patients in the US[34] - BCX17725, a targeted KLK5 inhibitor, is under development for Netherton syndrome, with initial Phase 1 data expected by the end of Q1 2026[59]

Accessibility StatementSkip Navigation more press release views with Request a Demo Also from this source Cardinal Health launches a new all-in-one solution for deep vein thrombosis and pulmonary embolism prevention Cardinal Health has announced the international launch of its Kendall SCD SmartFlowâ"¢ Compression System, the next generation of the Kendallâ"¢... Adds the country's leading urology MSO with over 750 providers to Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance an ...

120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced several milestones in its ORCA-OL long-term safet ...

Core Insights - Amarin Corporation will present new findings at the American Heart Association's Scientific Sessions 2025, reinforcing the efficacy of VASCEPA®/VAZKEPA® in cardiovascular risk reduction and highlighting the pleiotropic mechanism of action of Eicosapentaenoic Acid (EPA) [1][2] Group 1: Study Findings - New analyses from the REDUCE-IT study will evaluate the clinical benefit of Icosapent Ethyl (IPE) on cardiovascular outcomes with or without baseline use of aspirin [2] - Mechanistic studies will explore the anti-oxidant effects of EPA on lipoprotein(a) [Lp(a)] and its anti-inflammatory and endothelial-protective properties [2] Group 2: Presentation Details - Featured abstracts will be presented by academic collaborators, including a session on the efficacy of Icosapent Ethyl for cardiovascular risk reduction by aspirin use in REDUCE-IT [7] - Additional presentations will cover the effects of EPA on endothelial cells during inflammation and its impact on lipoprotein oxidation [5][8] Group 3: Company Overview - Amarin is a global pharmaceutical company focused on reducing the cardiovascular disease burden and advancing cardiovascular care, with a direct sales approach in the U.S. and an indirect distribution strategy internationally [5] - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising icosapent ethyl, launched in January 2020 for high-risk patients with persistent cardiovascular risk [6][9]

Accessibility StatementSkip Navigation Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ --Â Eli Lilly and Company (NYSE:Â LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply cha ...

Core Insights - The healthcare industry has shown resilience for investors, particularly with companies like Eli Lilly and Intuitive Surgical presenting strong long-term growth potential [3][8] Company Analysis: Eli Lilly - Eli Lilly has gained significant attention due to its successful GLP-1 franchise, despite facing pressures from potential U.S. government interventions aimed at lowering drug prices and recent pharma tariffs [4] - The company is making substantial investments in manufacturing, with plans for multibillion-dollar expansions in the U.S. to enhance production capacity for its popular medications [5] - Eli Lilly reported a 38% year-over-year revenue increase to $15.6 billion in Q2, alongside a 61% spike in non-GAAP earnings per share [6] - The company is advancing a promising drug pipeline in oncology, immunology, and neuroscience, with recent positive trial results for its oral GLP-1 treatment, orforglipron, which could attract patients who prefer non-injectable options [7] - The GLP-1 boom represents just the latest phase in Eli Lilly's growth story, which has a storied history in the pharmaceutical industry [8]

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the year-ago period. The consensus estimate for Pfizer's quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier, according to Benzinga Pro.On Oct. 10, Morgan Stanley analyst Terence Flynn maintained Pfizer with an Equal-Weight and lowered the price tar ...

Key TakeawaysPfizer (PFE) has launched a second federal antitrust lawsuit against Metsera and Novo Nordisk (NVO), alleging anticompetitive practices in the burgeoning $150 billion obesity drug market.Eaton (ETN) is set to acquire liquid cooling specialist Boyd Thermal for $9.5 billion, a strategic move to capitalize on the surging demand from AI data centers.Fed Governor Miran reiterated his view that the Federal Reserve's monetary policy is too restrictive, advocating for more aggressive 50 basis point int ...